Nanostructured Lipid Carriers Promote Percutaneous Absorption and Hair Follicle Targeting of Tofacitinib for Treating Alopecia Areata

    July 2024 in “ Journal of Controlled Release
    Qibin Li, Yameng Wang, Qing Guo, Jie Cao, Yangjun Feng, Xue Ke
    From the encyclopedia
    Tofacitinib →

    a JAK inhibitor for alopecia areata and other autoimmune conditions

    Alopecia Areata →

    autoimmune disorder causing patchy hair loss

    Studysummary In this study, researchers developed topical tofacitinib-loaded cationic lipid nanoparticles, which improved absorption and targeted hair follicles in an ex vivo pig ear model, showing promise in treating alopecia areata by reducing symptoms through the JAK/STAT pathway. Our plain-language summary of this paper — not a Tressless recommendation.
    The study developed tofacitinib-loaded cationic lipid nanoparticles (TFB-cNLCs) to enhance percutaneous absorption and hair follicle targeting for treating alopecia areata. Using ex vivo pig ear and in vitro follicle models, TFB-cNLCs demonstrated improved drug delivery to hair follicles, reduced IFN-γ-induced symptoms, and decreased CD8+NKG2D+T cells in a C3H mouse model, effectively reversing hair loss. This formulation offers a promising topical treatment, minimizing systemic side effects while maintaining efficacy.
    Discuss this study in the Community →

    Research cited in this study

    18 / 18 results